Apellis Pharmaceuticals Inc. (APLS)
Prediction: This Will Be the Best-Performing Growth Stock Over the Next 5 Years
24/7 Wall St. Insights Here are some candidates to be the best-performing growth stock over the next five years.
Apellis: Weighing Syfovre's Rapid Expansion Against Risks In The GA Market (Rating Upgrade)
Apellis Pharmaceuticals' Syfovre, despite initial safety concerns, shows strong revenue growth and is nearing profitability, making it a high-risk, high-reward investment. Syfovre's adjusted safety profile and bimonthly dosing offer advantages over Astellas' Izervay, though continued vigilance for retinal vasculitis is necessary. The Company's financial health is solid, with sufficient cash and assets to cover liabilities and fund operations until positive cash flow is achieved.
Apellis Pharmaceuticals: Assessing The Impact Of The Negative CHMP Opinion
Despite the CHMP's negative opinion on pegcetacoplan for GA in Europe, Apellis still has significant growth potential in the U.S. and other markets. The U.S. market remains crucial for Apellis, with SYFOVRE being the first approved GA treatment, expected to capture a large market share. Apellis' strong cash position and promising pipeline, including potential approvals for C3G and IC-MPGN, provide a buffer against the European setback.
Apellis Stock Down as Eye Drug Faces Third CHMP Rejection in the EU
APLS stock falls as the CHMP confirms its June 2024 negative opinion on the regulatory filing for intravitreal pegcetacoplan to treat GA in the EU.
Apellis: Rare Kidney Disease Data Leads To Possible First To Market
Positive results achieved from phase 3 VALIANT study, using pegcetacoplan for the treatment of patients with C3G and IC-MPGN. Apellis and its partner Sobi are expected to file regulatory applications of pegcetacoplan for the treatment of patients with C3G and IC-MPGN in 2025. U.S. net product revenues of SYFOVRE came in at $155 million in Q2 of 2024, which was a 12% increase quarter over quarter.
Apellis Pharmaceuticals, Inc. (APLS) Q2 2024 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q2 2024 Results Conference Call August 1, 2024 8:30 AM ET Company Participants Meredith Kaya - SVP of IR & Strategic Finance Cedric Francois - Co-Founder & CEO Adam Townsend - COO Caroline Baumal - Chief Medical Officer Tim Sullivan - CFO Conference Call Participants Jonathan Miller - Evercore Anupam Rama - J.P. Morgan Yigal Nochomovitz - Citigroup Steven Seedhouse - Raymond James Colleen Kusy - Baird Phil Nadeau - TD Cowen Ivy Wang - Jefferies Eliana Merle - UBS Annabel Samimy - Stifel Francois Brisebois - Oppenheimer Douglas Tsao - H.C.
Apellis (APLS) Q2 Earnings Beat, Syfovre Sales Drive Revenues
Apellis (APLS) reports better-than-expected second-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong sales of Syfovre.
Compared to Estimates, Apellis Pharmaceuticals (APLS) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Apellis Pharmaceuticals (APLS) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Apellis Pharmaceuticals, Inc. (APLS) Reports Q2 Loss, Tops Revenue Estimates
Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $1.02 per share a year ago.
Apellis Pharmaceuticals, Inc. (APLS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Apellis Pharmaceuticals (APLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apellis' (APLS) Syfovre Boost Sales, Regulatory Setbacks a Woe
Apellis' (APLS) revenues rise on the back of the robust uptake of Syfovre for the GA indication. However, the recent regulatory setback in the EU for pegcetacoplan to treat GA is a woe.
Apellis (APLS) Falls on Second Negative CHMP Opinion for GA Drug
Apellis (APLS) declines as CHMP issues a second negative opinion for the approval of intravitreal pegcetacoplan to treat GA in the EU. The company plans to seek re-examination of the same.
